Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000899923-25-000048
Filing Date
2025-05-07
Accepted
2025-05-06 20:48:53
Documents
78
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mygn-20250331.htm   iXBRL 10-Q 762776
2 EX-10.9 ex-109xmyriadxdonnellyrsua.htm EX-10.9 58939
3 EX-10.10 ex-1010xmyriadxdonnellypsu.htm EX-10.10 59847
4 EX-31.1 exhibit311-certificationof.htm EX-31.1 10445
5 EX-31.2 exhibit312-certificationof.htm EX-31.2 10434
6 EX-32.1 exhibit321-certificationpu.htm EX-32.1 6092
  Complete submission text file 0000899923-25-000048.txt   5069767

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mygn-20250331.xsd EX-101.SCH 38631
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mygn-20250331_cal.xml EX-101.CAL 57422
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mygn-20250331_def.xml EX-101.DEF 117323
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mygn-20250331_lab.xml EX-101.LAB 513810
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mygn-20250331_pre.xml EX-101.PRE 332520
81 EXTRACTED XBRL INSTANCE DOCUMENT mygn-20250331_htm.xml XML 578695
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-26642 | Film No.: 25918961
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)